Cooley advised Alentis Therapeutics, a clinical-stage biotechnology company developing treatments for Claudin-1 positive tumors and organ fibrosis, on its $181.4 million oversubscribed Series D financing round. Partners Brandon Fenn and Ryan Sansom led the Cooley team advising Alentis Therapeutics.